Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

The biotech industry faces a mix of clinical breakthroughs and regulatory challenges, headlined by Amylyx’s positive Phase 3 data for its GLP-1 blocker, Avexitide, which demonstrated a 55% reduction in hypoglycemic events following bariatric surgery. Conversely, Summit Therapeutics faces mounting pressure regarding its bispecific antibody, ivonescimab, as degrading progression-free survival data in China complicates its U.S. regulatory path. Meanwhile, the psychedelic sector continues its momentum with Definium’s successful Phase 3 trial for an LSD-based anxiety treatment. In the weight loss market, Eli Lilly is aggressively combating the illicit sale of its investigational drug, retatrutide, by reporting thousands of illegal online listings to authorities. Additionally, the Prader-Willi community faces uncertainty following reports of seven patient deaths associated with Neurocrine’s therapy, Vicat, prompting calls for thorough investigations and informed prescribing practices.